Sign in Subscribe
Drugs

Fresh Data on Brain Cancer Treatment in Children

Strategic Insights

— 1 min read

Recent research, led by A. Broniscer and colleagues from the St. Jude Children's Research Hospital, has shed light on the effectiveness of a treatment combination for brain cancer in children. The study, published in Clinical Cancer Research, aimed to estimate the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of temozolomide combined with O(6)-benzylguanine in pediatric patients.

Key Takeaways:

  • The study involved two strata of patients: Str1 with high-grade/brainstem glioma and Str2 with medulloblastoma, with a median age at study entry of 8.6 and 11.3 years, respectively.
  • The estimated MTD of temozolomide for Str1 and Str2 was 562 and 407 mg/m^2, respectively, with recommended doses for phase II investigations being 472 and 355 mg/m^2, respectively.
  • DLTs were predominantly neutropenia and thrombocytopenia, but three patients with gliomas experienced centrally confirmed partial responses to therapy.
  • Temozolomide and 5-triazeno imidazole carboxamide (MTIC) exposures were statistically associated with temozolomide dosage, indicating the importance of pharmacokinetic analyses.
  • The current schedule of temozolomide and O(6)-benzylguanine is safe and showed modest activity against recurrent brain tumors in children.

Statistics:

  • A total of 44 and 26 eligible patients were enrolled on Str1 and Str2, respectively.
  • 3 patients with gliomas experienced centrally confirmed partial responses to therapy.
  • 4 patients completed all planned therapy.
  • Temozolomide and MTIC exposures were statistically associated with temozolomide dosage.
  • The doses recommended for phase II investigations are 472 and 355 mg/m^2, respectively.

Sources:

  • Broniscer, A., et al. (2007). Phase I trial of single-dose temozolomide and continuous administration of O(6)-benzylguanine in children with brain tumors: a pediatric brain tumor consortium report. Clinical Cancer Research, 13(22 Pt 1), 6712-8.
  • American Association for Cancer Research. (Publisher contact information). American Association Cancer Research, 615 Chestnut St., 17TH Floor, Philadelphia, PA 19106-4404, USA.
  • Health & Medicine Week (2007). Fresh Data on Brain Cancer are Presented.

Read more